Skip to main content

Table 1 Clinical features, disease state, response in the clinic and in vitro of patient-obtained leukemia treated with pancratistatin.

From: Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells

Patient # Age Clinical Diagnosis % Blasts Clinical Response Exposure % Apoptosis
1 60 AML - M3 85% censored 24 h 64.9 ± 4.2
2 81 AML-M2 20% NR 24 h 33.5 ± 7.7
3 53 AMoL-M5a 96% CR 24 h 46.5 ± 7.9
4 73 CML 9% censored 24 h 63.9 ± 2.2
5 23 AML-M5a 70% NR 24 h 30.6 ± 1.6
6 66 ALL-L3 34% NR 48 h 61.8 ± 9.8
7 62 CMML-M4 32% NR 48 h 17.7 ± 2.7
8 74 AML-M2 60% NR 48 h 48.6 ± 6.7
9 45 AML 84% censored 48 h 63.9 ± 4.2
10 57 AML-M3 43% PR 48 h 70.8 ± 5.9
11 68 AML-M2 n/a CR 48 h 46.8 ± 12.2
12 80 Mantel cell lymphoma 0% censored 48 h 35.2 ± 6.6
13 47 AML 44% censored 48 h 37.3 ± 7.7
14 71 AML-M0, relapsed 52% relapsed 48 h 45.3 ± 11.3
15 65 AML-MDS, relapsed 48% CR 48 h 37.3 ± 8.5